News

Biogen is acquiring Karyopharm Therapeutics’ KPT-350 and other potential treatments for neurodegenerative diseases such as ALS. “As a global innovative leader in neuroscience that brings world-class capabilities in developing and commercializing products targeting a broad range of neurological conditions, Biogen is well suited to further advance the development of KPT-350,” Michael…

Scientists at the University of Edinburgh discovered that the human neuromuscular junction (NMJ) — a cell connection between neurons and muscle that enables motion — is different in size and structure than other mammals, including mice, which are routinely used in research. “Our findings provide unique insights into the…

An international team has learned how the body activates a protein responsible for limiting muscle growth, a finding that could lead to therapies to improve ALS patients’ muscle function. The protein, called GDF8 or myostatin, determines both the number of muscle fibers the body produces and the fibers’ size. Researchers’…

Amyotrophic lateral sclerosis (ALS) patients experiencing feelings of apathy reported lower quality of life (QoL), particularly regarding achievements in life and community connectedness, a new Australian study reports. The research, “Apathy and its impact on patient outcome in amyotrophic lateral sclerosis,” appeared in the Journal of…

A naturally occurring enzyme improves ALS symptoms in mice and could lead to effective therapies in humans, a study suggests. The research, “Deletion of NAMPT in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death,” appeared in the journal Cell Reports. Data from…